Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/222823
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Filanesib for the treatment of multiple myeloma |
Autor: | Algarín, Esperanza M.; Hernández-García, Susana CSIC; Garayoa, Mercedes CSIC ORCID ; Ocio, Enrique M. CSIC ORCID | Fecha de publicación: | 2020 | Editor: | Taylor & Francis | Citación: | Expert Opinion on Investigational Drugs 29(1): 5-14 (2020) | Resumen: | [Introduction]: Kinesin spindle protein (KSP) is indispensable for the proper separation of spindle poles during mitosis. Importantly, this protein is expressed only in cells undergoing cell division and hence represents an appealing target for the treatment of cancer. Many KSP inhibitors have demonstrated a strong antitumoral effect in vitro, however, they have exhibited only limited activity in clinical trials. By contrast, the KSP inhibitor filanesib has demonstrated clinical efficacy in patients with multiple myeloma (MM). [Areas covered]: This article provides a comprehensive overview about the progress to date in the preclinical and clinical development of filanesib for the treatment of cancer, and particularly, MM. [Expert opinion]: Responses observed with filanesib alone or in combination with dexamethasone were encouraging in MM. However, the subsequent appearance of highly effective novel agents such as monoclonal antibodies, has hindered the development of agents such as filanesib that exhibit a more limited activity. Nevertheless, filanesib has shown interesting results for some patients when combined with carfilzomib and pomalidomide. Most importantly, the availability of a biomarker of response such as alpha 1-acid glycoprotein (AAG), could be key to the identification of patients that could benefit most from these combinations. |
Versión del editor: | https://doi.org/10.1080/13543784.2020.1703179 | URI: | http://hdl.handle.net/10261/222823 | DOI: | 10.1080/13543784.2020.1703179 | ISSN: | 1354-3784 | E-ISSN: | 1744-7658 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
18
checked on 13-abr-2024
WEB OF SCIENCETM
Citations
18
checked on 28-feb-2024
Page view(s)
142
checked on 18-abr-2024
Download(s)
46
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.